Current Issues of Pharmacy and Medical Sciences

Advances in surgery for peritoneal surface malignancies

Curr Issues Pharm Med Sci., Vol. 30, No. 4, 171-172

Jerzy Mielko1, Karol Rawicz-Pruszynski1, Tomasz Jastrzebski2, Wojciech P. Polkowski1

1 Department of Surgical Oncology, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
2 Department of Surgical Oncology, Medical University of Gdansk, Poland

DOI: 10.1515/cipms-2017-0031


Currently, patients with isolated peritoneal surface malignancies are treated with a combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). This combination should now be considered the standard of care for appendiceal cancers (including pseudomyxoma), colorectal cancer and peritoneal mesothelioma, while patients with peritoneal metastases from ovarian or gastric cancer may be treated within clinical trials. At present, 8 clinical centres in Poland perform CRS and HIPEC. The unanswered problems of combined intraperitoneal therapy were an impulse for the organization of the 4th International Conference “Advances in Surgical Oncology” that was held on November 23-24, 2017, in Lublin (Poland), and the Polish chapter of the Peritoneal Surface Oncology Group International (PSOGI) was established as a result of this meeting. This special issue of the Current Issues in Pharmacy and Medical Sciences is dedicated to the current therapeutic difficulties discussed during the two days of the conference – experiences that were exchanged to set in motion further directions for the improvement of intraperitoneal treatment.

Full text


adenomatosis, peritoneal surface malignancies, gastric cancer, colorectal cancer, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy


July 2019

Mon Tue Wed Thu Fri Sat Sun
01 02 03 04 05 06 07
08 09 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31